Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 +0.67%77 Net Margin % is 28.52% as of Mar. 2026, which is 2% above its 10-year median of 27.92. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Getein Biotech ranks better than 90.7% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Getein Biotech's Net Income for the
three
months ended in Mar. 2026 was ¥76 Mil. Getein Biotech's Revenue for the
three
months ended in Mar. 2026 was ¥268 Mil. Therefore, Getein Biotech's net margin for the quarter that ended in Mar. 2026 was 28.52%.
The historical rank and industry rank for Getein Biotech's Net Margin % or its related term are showing as below:
SHSE:603387'
s Net Margin % Range Over the Past 10 Years
Min: 19.2 Med: 27.92 Max: 39.7
Current: 21.64
SHSE:603387's Net Margin % is ranked better than 90.7% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs SHSE:603387: 21.64
Getein Biotech (SHSE:603387) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Getein Biotech Net Margin % Related Terms
Getein Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Getein Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Getein Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Getein Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a Net Margin % of 28.52% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Getein Biotech and its competitors. This is near median its historical median of 27.92. Over the past decade, Getein Biotech's Net Margin % has ranged from 19.20 to 39.70. According to the industry distribution chart, Getein Biotech ranks #76 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 9.3%.
Is Getein Biotech's Net Margin % too high?
Getein Biotech's current Net Margin % of 28.52% is near median its 10-year median of 27.92. Over the past 10 years, this metric has ranged from a low of 19.20 to a high of 39.70. The Medical Devices & Instruments industry median Net Margin % is 2.05. Getein Biotech's value of 28.52% is 1291.2% above this industry median. Based on the distribution chart, Getein Biotech ranks #76 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #76 out of 817 companies for Net Margin %. This places Getein Biotech in the top 9% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.05. Getein Biotech's value of 28.52% is 1291.2% above this benchmark. Historically, Getein Biotech's own Net Margin % has ranged from 19.20 to 39.70 over the past decade. While the company's 10-year median is 27.92 vs. the industry median of 2.05, Getein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.05, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current Net Margin % of 28.52% is 1291.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current Net Margin % is 28.52%, which is near median its own 10-year median of 27.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.96 — trading 18.4% above its estimated fair value. The current Net Margin % is 28.52%, which is near median its 10-year median of 27.92 and 1291.2% above the Medical Devices & Instruments industry median of 2.05. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Net Margin % is 28.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥8.96 is trading 18.4% above its estimated GF Value™ of ¥7.57.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
Net Margin %: 28.52% (near median its 10-year median of 27.92)
GF Value™: ¥7.57 vs. price of ¥8.96 (18.4% above fair value)
Industry Position: 1291.2% above the Medical Devices & Instruments median (#76 of 817)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score
Get the complete analysis for SHSE:603387
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
